TRIKAFTA is a life saving drug, used for the chronic treatment of Cystic Fibrosis (CF), for patients aged 6 and older, with at least one F508del mutation or mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene.

Families of eligible children who are aged 6 to 11 year olds with Cystic Fibrosis now have access to TRIKAFTA through the Pharmaceutical Benefits Scheme (PBS). Doctors and scientists expect TRIKAFTA will benefit more than 500 children per year. TRIKAFTA is expected to improve quality of life and improve life expectancy of CF patients. 

Just 2 years ago, TRIKAFTA was only approved for people aged 12 or older, and in such a small amount of time, it is now accepted for a wider range of children around Australia. Without subsidy, TRIKAFTA would have cost families up to $250 000 per year, now it will cost families just over $5000 per year. This would not have been possible with the ongoing support and donations, and for that, we THANK YOU. 

To read further please visit this link https://www.cysticfibrosis.org.au/what-we-do/drug-pipeline/elexacaftor-tezacaftor-ivacaftor-(trikafta%E2%84%A2)